Allogene Therapeutics (ALLO) Interest & Investment Income (2021 - 2026)

Allogene Therapeutics (ALLO) has 6 years of Interest & Investment Income data on file, last reported at $3.6 million in Q1 2026.

• For the quarter ending Q1 2026, Interest & Investment Income fell 35.22% year-over-year to $3.6 million; the trailing twelve-month figure through Mar 2026 stood at $17.3 million (down 14.28% YoY), and the FY2025 full-year result was $19.3 million, down 4.29% from the prior year.
• Interest & Investment Income eased to $3.6 million in Q1 2026, from $3.7 million in the prior quarter.
• In the past five years, Interest & Investment Income ranged from a high of $6.7 million in Q3 2024 to a low of $315000.0 in Q2 2022.
• A 5-year average of $3.9 million and a median of $3.8 million in 2023 frame the typical range for Interest & Investment Income.
• Across the five-year window, Interest & Investment Income soared 1382.26% in 2022 and plunged 51.68% in 2024, its largest moves.
• Tracing ALLO's Interest & Investment Income over 5 years: stood at $2.8 million in 2022, then soared by 127.24% to $6.3 million in 2023, then sank by 51.68% to $3.0 million in 2024, then climbed by 20.91% to $3.7 million in 2025, then dropped by 2.38% to $3.6 million in 2026.
• Business Quant data shows ALLO's Interest & Investment Income at $3.6 million in Q1 2026, $3.7 million in Q4 2025, and $3.9 million in Q3 2025.